You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • FRI0367 BCX4208 added to allopurinol increases response rates in patients with GOUT who fail to reach goal range serum uric acid on allopurinol alone: A randomized, double-blind, placebo-controlled trial

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Posters
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
FRI0367 BCX4208 added to allopurinol increases response rates in patients with GOUT who fail to reach goal range serum uric acid on allopurinol alone: A randomized, double-blind, placebo-controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Becker M, Hollister A, Terkeltaub R, et al
FRI0367 BCX4208 added to allopurinol increases response rates in patients with GOUT who fail to reach goal range serum uric acid on allopurinol alone: A randomized, double-blind, placebo-controlled trial
Annals of the Rheumatic Diseases 2013;71:438.